logo
ScreenersREIT EarningsREIT SectorsMarketplaceLearn
Logo

Travere Therapeutics, Inc.

TVTX

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients witā€¦ read more

Healthcare

Biotechnology

10 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$18.77

Price

-0.27%

-$0.05

$18.82

Previous Close

$18.83

Open

Premium

52w Discount
Market Cap

$1.673b

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$333.866m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$169.056m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$2.04

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$32.747m

$555.309m

Assets

$522.562m

Liabilities

$399.573m

Debt
Debt to Assets

72.0%

-3.2x

Debt to EBITDA
Free Cash Flow

-$118.279m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.